Daiichi Sankyo Company, Limited (TYO:4568)
3,669.00
-38.00 (-1.03%)
Mar 28, 2025, 3:30 PM JST
Daiichi Sankyo Company Revenue
Daiichi Sankyo Company had revenue of 484.84B JPY in the quarter ending December 31, 2024, with 8.48% growth. This brings the company's revenue in the last twelve months to 1.80T, up 19.46% year-over-year. In the fiscal year ending March 31, 2024, Daiichi Sankyo Company had annual revenue of 1.60T with 25.28% growth.
Revenue (ttm)
1,795.99B
Revenue Growth
+19.46%
P/S Ratio
3.89
Revenue / Employee
95.91M
Employees
18,726
Market Cap
6,887.49B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Mar 31, 2024 | 1,601.69B | 323.21B | 25.28% |
Mar 31, 2023 | 1,278.48B | 233.59B | 22.36% |
Mar 31, 2022 | 1,044.89B | 82.38B | 8.56% |
Mar 31, 2021 | 962.52B | -19.28B | -1.96% |
Mar 31, 2020 | 981.79B | 52.08B | 5.60% |
Mar 31, 2019 | Pro | Pro | Pro |
Mar 31, 2018 | Pro | Pro | Pro |
Mar 31, 2017 | Pro | Pro | Pro |
Mar 31, 2016 | Pro | Pro | Pro |
Mar 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionDaiichi Sankyo Company News
- 6 days ago - Pharmaceutical Firms Say UK Investment Is 'Unlikely' Unless Payment Levy Is Adressed - Benzinga
- 16 days ago - Nosis Biosciences Announces Research Collaboration and Option Agreement with Daiichi Sankyo to Develop Cell-Targeted RNA Medicines - Business Wire
- 24 days ago - Daiichi Sankyo and AstraZeneca report positive result in trial for its gastric cancer treatment - Seeking Alpha
- 24 days ago - ENHERTU® Demonstrated Statistically Significant and Clinically Meaningful Improvement in Overall Survival in Patients with HER2 Positive Metastatic Gastric Cancer at Interim Analysis of DESTINY-Gastric04 Phase 3 Trial - Benzinga
- 27 days ago - AstraZeneca's metastatic breast cancer treatment gets EU recommendation - Seeking Alpha
- 7 weeks ago - AstraZeneca Blames 'Toxic' Climate As It Walks Away from Over $550 Million UK Vaccine Plant - Benzinga
- 7 weeks ago - Q3 2025 Daiichi Sankyo Co Ltd Earnings Presentation Transcript - GuruFocus
- 7 weeks ago - Incoming Daiichi Sankyo CEO shares business roadmap going forward - CNBC